{"disease":{"id":"active-tuberculosis","name":"active tuberculosis"},"drugs":{"marketed":[{"drug_id":"cycloserine","indication_name":"Active Pulmonary Tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cycloserine","indication_name":"Active Extrapulmonary Tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pyrazinamide","indication_name":"Initial treatment of active tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrazinamide","generic_name":"PYRAZINAMIDE","company_name":"Dava Pharms Inc","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"rifampicin","indication_name":"Inactive tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rifadin","generic_name":"Rifampicin","company_name":"Sanofi Aventis Us","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"isoniazid","indication_name":"Inactive tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoniazid","generic_name":"ISONIAZID","company_name":"Epic Pharma Llc","drug_phase":"marketed","molecular_target":"Myeloperoxidase","drug_class":"Antimycobacterial [EPC]","quality_score":69,"revenue":null,"mechanism":"Isoniazid works by inhibiting the enzyme myeloperoxidase, which is essential for the survival of Mycobacterium tuberculosis."},{"drug_id":"isoniazide","indication_name":"Inactive tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"isoniazide","company_name":"Bridge BioResearch Ltd.","drug_phase":"phase_2","molecular_target":"Myeloperoxidase, Cytochrome P450 3A4, Cytochrome P450 3A5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04048018","title":"Performance Evaluation of the VIDAS TB-IGRA Assay.","phase":"","overall_status":"COMPLETED","enrollment_count":2401,"lead_sponsor_name":"BioMérieux","has_results":false},{"nct_id":"NCT02898623","title":"Serological Test for the Diagnosis of TB","phase":"","overall_status":"TERMINATED","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT06408129","title":"COMPArison of Screening Strategies for Active TuBerculosis (COMPASS-TB)","phase":"","overall_status":"COMPLETED","enrollment_count":580,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05045391","title":"Pulmonary Aspergillosis in Tuberculosis Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","has_results":false},{"nct_id":"NCT06838780","title":"Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":192,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03271567","title":"Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07058233","title":"Oral Nutritional Supplementation and Weight Changes During Therapy in Malnourished Patients With Resistant Tuberculosis: A Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"RSUP Persahabatan","has_results":false},{"nct_id":"NCT05840809","title":"Pharmacokinetics of Drugs Used to Treat Drug Sensitive Tuberculosis in Breastfeeding Mother-infant Pairs","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Liverpool","has_results":false},{"nct_id":"NCT05048381","title":"miRNA in Sweat, a Novel Digital Biomarker for Detection of Active Tuberculosis (TB)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}